Business ❯ Finance ❯ Stock Market

Pharmaceutical Stocks

Novo Nordisk Pfizer Market Performance Tariffs Market Reactions Eli Lilly Recursion Pharmaceuticals Vertex Pharmaceuticals Vaccine Manufacturers AstraZeneca Amgen Sun Pharma Moderna Pfizer Inc. Sun Pharmaceutical Ltd. Drug Pricing Policies European Drugmakers Dr. Reddys Laboratories Biotech Stocks SPARC Shares Dr. Reddy's Laboratories Investment Trends Hims & Hers Sarepta Therapeutics Sigachi Industries Dr Reddy's Laboratories Jubilant Pharmova Viking Therapeutics Eli Lilly and Co. Cipla Piramal Pharma Ionis Pharmaceuticals Market Impact AbbVie COVID-19 Vaccine Makers Eli Lilly and Novo Nordisk Wockhardt Ltd. Dr Reddy's Lab Sangamo Therapeutics Lupin Pharmaceuticals Eli Lilly & Company Mira Pharmaceuticals Praxis Precision Medicines, Inc. Novo Nordisk and Eli Lilly Omeros Teva Pharmaceutical Sanofi SA Jazz Pharmaceuticals Investment Genmab Stock Sanofi Novartis AG Laurus Labs Eli Lilly (LLY) Eli Lilly and Company Ultragenyx Pharmaceutical Vanda Pharmaceuticals Corvus Pharmaceuticals Bristol-Myers Squibb Company Gilead Sciences Bristol Myers Squibb Zevra Therapeutics Investor Reactions Emcure Pharmaceuticals COVID Vaccine Manufacturers Rocket Pharmaceuticals Company Performance Sudarshan Pharma Industries Ltd Hims & Hers Health Market Trends Vaccine Makers Competitor Analysis Sudarshan Pharma Industries

Bristol Myers Gains Analyst Support as 2026 Catalysts Offset Patent-Cliff Worries

Fresh price-target hikes follow positive Camzyos data in adolescents.

Corvus Leaps After Soquelitinib Shows Strong Phase 1 Cohort 4 Eczema Data

Novo’s Wegovy Pill Posts Quick Uptake, Boosting Shares as Oral GLP‑1 Battle Nears

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

FDA Approves Novo Nordisk’s Wegovy Pill, First Oral GLP-1

JPMorgan Upgrades Recursion, Raises Target to $11 as Shares Surge on AI Drug Signals

Pfizer Sets 2026 Targets Below Wall Street as COVID Sales Fade, Patent Pressure Builds

Sanofi Ends PPMS Bid After Tolebrutinib Fails Phase 3 as FDA Delays Review for nrSPMS

China Approves Sanofi’s Qfitlia for Hemophilia A Prophylaxis and Cablivi for aTTP

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Pharvaris’ Oral HAE Drug Deucrictibant Delivers Rapid Relief in Pivotal Phase 3

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

Zymeworks Shifts to Royalty Model After Ziihera’s Phase 3 Win in HER2‑Positive Gastroesophageal Cancer

Teva Tops Q3 Views, Lifts Austedo Outlook as It Narrows Full-Year Sales Range

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises

Vertex Tops Q3 Estimates on CF Franchise as New Drugs Miss and Outlook Edges Higher

Praxis Drug Succeeds in Two Phase 3 Essential Tremor Trials, FDA Filing Planned

Mira Pharmaceuticals Soars After Oral Pain Drug Outperforms Morphine in Preclinical Test

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion